Antipsychotic

Jul 31, 2026

Summary FDA approved Otsuka’s SIMTRIYO (centanafadine) on July 24, 2026, for ADHD treatment in patients aged ≥6 years weighing at least 20 kg. First-in-class norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI), introducing a novel triple-mechanism approach. Approval backed by four Phase 3 trial...

Mar 02, 2026

Summary The U.S. FDA approved Vanda Pharmaceuticals’ BYSANTI (milsaperidone) for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder. BYSANTI is built on the pharmacologic framework of FANAPT (iloperidone). Vanda’s stock surged nearly 40% after BYSANTI’s approval,...